Care with intrathecal trastuzumab

Lancet Oncology

Volumn 7, Issue 11, 2006, Pages 888-

  Siderov, Jim ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYL ALCOHOL; DRUG PRESERVATIVE; EXCIPIENT; HISTIDINE; POLYSORBATE; TRASTUZUMAB;

ANAPHYLAXIS; CAUDA EQUINA; DEMYELINATION; DRUG FORMULATION; FIBROSIS; HUMAN; LETTER; MALIGNANT NEOPLASTIC DISEASE; NEUROTOXICITY; PARAPLEGIA; POWDER; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZYL ALCOHOL; HUMANS; INJECTIONS, SPINAL; PRESERVATIVES, PHARMACEUTICAL; SPINAL CORD; SPINAL CORD NEOPLASMS;

EID: 33750401155     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70917-2     Document Type: Letter

References (5)

1. Platini C., Long J., and Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7 (2006) 778-780
2. Roche products Pty Ltd. Herceptin (trastuzumab) Australian approved product information. Therapeutic Goods Administration approved amendment (21 April, 2006), Roche products Pty Ltd, Sydney
3. Electronic Medicines Compendium. http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc.asp &documentid=3567 (accessed Sept 20, 2006)
4. In: McEvoy G. (Ed). American Hospital Formulary Service (AHFS) Drug Information (2006), American Society of Health-System Pharmacists, Bethesda 1209-1215
5. Hetherington N., and Dooley M. Potential for patient harm from intrathecal administration of preserved solutions. Med J Aust 173 (2000) 141-143